Scientific Advisory Board

The Scientific Advisory Board assists iNOVA4Health in achieving outstanding research through the evaluation of the progress and plans, providing advice on strategic decisions and making suggestions for adjustments and future developments.

 

Professor Dr. Seppo Ylä-Herttuala

Prof. Seppo Yla-Herttuala M.D., Ph.D. is Professor of Molecular Medicine for A.I. Virtanen Institute for Molecular Sciences and Department of Medicine, University of Kuopio, Kuopio, Finland. Dr. Yla-Herttuala is an Internationally Recognized Leader in cardiovascular gene therapy. His team was among the first to use adenovirus-mediated gene transfer in human arteries and since then, he has conducted several clinical trials in cardiovascular gene therapy. His group is also widely recognized for basic and applied biology research related to vascular endothelial growth factors, especially with newer members of the growth factor family. Dr. Ylä-Herttuala was one of Ark Therapeutics Group plc's co-founders in 1997. He has been Member of Scientific Advisory Board of Cardium Therapeutics Inc., since November 11, 2006. Dr. Yla-Herttuala served as a Non-Executive Director of ARK Therapeutics Group PLC from March 8, 2004 to May 15, 2013. He serves on the editorial boards of several major US and European cardiovascular and gene therapy journals. He has published over 250 scientific papers and articles related to cardiovascular diseases, VEGFs, Atherosclerosis, rest enosis and gene therapy.

 

Dr. Clive Wood

Dr. Wood is a Corporate Senior Vice President, Head of Research at Boehringer Ingelheim. He a top senior scientist with extensive experience in research and development of biopharmaceuticals. He has worked in several pharmaceutical companies, and has also close ties with the University. He is Adjunct Professor at the School of Medicine of Boston University. He has a long list of patents and publications in the best scientific journals.

 

Professor Dr. Christof von Kalle

Professor Dr. Christof Von Kalle MD, PhD serves as Chairman at the department of Translational Oncology at the German Cancer Research Center and as Director of National Center for Tumor Diseases at the University Hospital Heidelberg. He has been Group Leader of Section of Hematopoiesis and Gene Transfer, Institute for Molecular Medicine, Freiburg University, Germany since 2000. He is trained in the areas of internal medicine, hematology and molecular biology. His research areas includes transplantation of hematopoietic stem cells, the roll of bone marrow stem cells during tissue repair and cancer, and finally development of gene transfer strategies for therapeutic use related to acquired and inherited genetic disorders. Since 1996, he has been Senior Clinical Investigator of Gene Therapy Program, and Senior Medical Staff Fellow of Department of Internal Medicine, Freiburg University Medical School, Germany. He has been Program Leader "Gene and Molecular Therapy" Cincinnati Children's Hospital Medical Center for Experimental Hematology, USA (Prof. Dr. David Williams) since 2002.

 

Professor Dr. Philip W. Ingham, FRS, FMedSci, Hon. FRCP

Prof Philip Ingham is the Toh Kian Chui Distinguished Professor and Professor of Developmental Biology at Lee Kong Chian School of Medicine, Nanyang Technological University. Prior to this appointment, he was the founding Director of the MRC Centre for Developmental & Biomedical Genetics at the University of Sheffield, UK, and Deputy Director of the A*STAR Institute of Molecular and Cell Biology, where he still retains an appointment. Prof Ingham is internationally recognised for his contributions to the developmental genetics of both Drosophila and zebrafish and has published more than 160 papers in top-ranking journals, including four Citation Classics.

 

Professor Dr. Diogo Lucena

Full Professor at the Nova School of Business and Economics – Portugal. At Faculdade de Economia of Universidade Nova de Lisboa, Prof. Lucena was member of the Installation Committee, Dean for Students Affairs, Director of MBA Programme, Academic Dean and Director. He was also member of Comissão Instaladora of the Faculty of Law and Vice-Rector of the Universidade Nova de Lisboa. He has been a consultant for private and public institutions and organizations, and Trustee of the Caloust Gulbenkian Foundation.

 

Professor Dr. Pilar Garin-Chesa

Professor Dr. Pilar Garin-Chesa is an MD, PhD with extensive experience in the discovery and development of Biomarkers & Translational Research in Oncology. At present she is a Senior Scientific Expert at the Research Institute of Molecular Pathology (IMP), Vienna. She has worked for several year at Boehringer Ingelheim Oncology Research, and as Guest Professor in the Department of Pathology at the University Hospital in Vienna. A Fulbright Scholar with past appointments as an Assistant Attending Experimental Pathologist at Memorial Sloan-Kettering Cancer Center in New York and Assistant Member, Ludwig Institute for Cancer Research, New York, USA and Associate Professor of Histology and Cell Biology at the University of Zaragoza, Spain.